STEMLINE THERAPEUTICS INC: 10-Q filed 2017-11-09

Name: STEMLINE THERAPEUTICS INC: 10-Q filed 2017-11-09
Creator: STEMLINE THERAPEUTICS INC

What STEMLINE THERAPEUTICS INC reported in its quarterly report filed 2017-11-09 (fiscal Q3 2017): 28 published measures, 76 facts as tagged in accession 0001104659-17-067392.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-11-09
Fiscal period: fiscal Q3 2017
Accession: 0001104659-17-067392 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All STEMLINE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	80,830,340	USD
At 2016-12-31	68,119,098	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-09-30	14,586,189	USD
At 2016-12-31	10,396,013	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-09-30	66,244,151	USD
At 2016-12-31	57,723,085	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-09-30	10,265,356	USD
At 2016-12-31	10,316,064	USD
At 2016-09-30	9,127,991	USD
At 2015-12-31	13,376,196	USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-35,894,434	USD	273
2016-01-01 to 2016-09-30	-23,315,577	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	48,371,064	USD	273
2016-01-01 to 2016-09-30	171,332	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-12,527,338	USD	273
2016-01-01 to 2016-09-30	18,896,040	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-182,526,389	USD
At 2016-12-31	-135,742,607	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-8,822	USD	92
2016-01-01 to 2016-09-30	-35,578	USD	274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-09-30	145,968	USD
At 2016-12-31	22,531	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	6,178,079	USD	273
2016-01-01 to 2016-09-30	5,666,813	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-16,270,704	USD	92
2017-01-01 to 2017-09-30	-46,619,661	USD	273
2016-07-01 to 2016-09-30	-10,065,428	USD	92
2016-01-01 to 2016-09-30	-28,758,336	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	66,123,635	USD
At 2016-12-31	47,169,711	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	14,465,156	USD
At 2016-12-31	10,253,813	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	12,417,652	USD	92
2017-01-01 to 2017-09-30	33,517,006	USD	273
2016-07-01 to 2016-09-30	7,176,960	USD	92
2016-01-01 to 2016-09-30	20,585,659	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	25,271,907	shares
At 2016-12-31	19,219,223	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit
At 2017-09-30	-87,683	USD
At 2017-06-30	-120,897	USD
At 2016-12-31	-99,802	USD
At 2016-09-30	-47,512	USD
At 2016-06-30	-35,159	USD
At 2015-12-31	-153,690	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2017-09-30	612,879	USD
At 2016-12-31	486,586	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2017-09-30	466,911	USD
At 2016-12-31	464,055	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2017-09-30	212,305	USD
At 2016-12-31	212,305	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2017-09-30	121,033	USD
At 2016-12-31	142,200	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2017-09-30	598,356	USD
At 2016-12-31	290,747	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-16,056,147	USD	92
2017-01-01 to 2017-09-30	-46,079,093	USD	273
2016-07-01 to 2016-09-30	-9,932,044	USD	92
2016-01-01 to 2016-09-30	-28,329,487	USD	274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-16,022,933	USD	92
2017-01-01 to 2017-09-30	-46,066,974	USD	273
2016-07-01 to 2016-09-30	-9,935,575	USD	92
2016-01-01 to 2016-09-30	-28,187,731	USD	274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-16,056,147	USD	92
2017-01-01 to 2017-09-30	-46,079,093	USD	273
2003-08-08 to 2017-09-30	194,000,000	USD	5168
2016-07-01 to 2016-09-30	-9,923,222	USD	92
2016-01-01 to 2016-09-30	-28,293,909	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	4,152,449	USD	92
2017-01-01 to 2017-09-30	14,000,854	USD	273
2016-07-01 to 2016-09-30	3,187,869	USD	92
2016-01-01 to 2016-09-30	8,914,630	USD	274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	952	USD	92
2017-01-01 to 2017-09-30	2,856	USD	273
2016-07-01 to 2016-09-30	952	USD	92
2016-01-01 to 2016-09-30	79,306	USD	274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	48,242,214	USD	273

Inspect the source

Entity: STEMLINE THERAPEUTICS INC / CIK 0001264587
Captured: 2026-09-22 19:43 UTC
SEC response SHA-256: 4bc563f579ac3611fca3a4b0f91dded31bf19c0e78ed6a10086fa540610de496

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001264587.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))